Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31496692 | 0.94 | CHRM2 (0.54) | CHRM2PAOXTDP1SIGMAR1TMEM97 | |
| SCHEMBL18339127 | 0.88 | SIGMAR1 (0.41) | SIGMAR1TMEM97APPACKR3DNM1 | |
| SCHEMBL25331905 | 0.85 | CHRM2 (0.47) | CHRM2PAOXSIGMAR1TMEM97APP | |
| SCHEMBL25206001 | 0.84 | SIGMAR1 (0.39) | SIGMAR1TMEM97APPACKR3OPRM1 | |
| SCHEMBL12629215 | 0.81 | DNM1 (0.47) | CHRM2PAOXACKR3DNM1 | |
| SCHEMBL24102748 | 0.81 | TDP1 (0.50) | CHRM2PAOXTDP1CHEK1DAPK3 | |
| SCHEMBL14067585 | 0.81 | ALDH1A1 (0.50) | CHRM2PAOXTDP1CHEK1DAPK3 | |
| SCHEMBL13037025 | 0.81 | EPHX1 (0.47) | CHRM2PAOXTDP1SIGMAR1TMEM97 | |
| SCHEMBL14067583 | 0.81 | ALDH1A1 (0.50) | CHRM2PAOXTDP1CHEK1DAPK3 | |
| SCHEMBL19834202 | 0.81 | SIGMAR1 (0.40) | SIGMAR1TMEM97APPACKR3DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2278989-B1 | ORITAVANCIN FOR INHIBITING AND TREATING BIOFILMS | MELINTA THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200115372-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3411080-A2 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | Arrakis Therapeutics, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20180265911-A1 | TRIPTYCENE DERIVATIVES FOR NUCLEIC ACID JUNCTION STABILIZATION | UNIV PENNSYLVANIA (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3352872-A1 | TRIPTYCENE DERIVATIVES FOR NUCLEIC ACID JUNCTION STABILIZATION | The Trustees of the University of Pennsylvania (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2018006074-A2 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| WO-2017136450-A2 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017053982-A1 | TRIPTYCENE DERIVATIVES FOR NUCLEIC ACID JUNCTION STABILIZATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2011060228-A1 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110046041-A1 | METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS | TARGANTA THERAPEUTICS CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2278989-A2 | METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS | Targanta Therapeutics Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009126502-A2 | METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS | TARGANTA THERAPEUTICS CORP. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | CHRM2 4883/4885PAOX 2279/4885TDP1 686/4885 |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | CHRM2 4596/4885PAOX 2396/4885TDP1 70/4885 |
| US-20200115372-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | CHRM2 4883/4885PAOX 2279/4885TDP1 686/4885 |
| US-20110046041-A1 | METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS | OGT, OSTC, OGA | CHRM2 4696/4885PAOX 4518/4885TDP1 2235/4885 |
| US-20180265911-A1 | TRIPTYCENE DERIVATIVES FOR NUCLEIC ACID JUNCTION STABILIZATION | TRDMT1, TARBP1, DTYMK | CHRM2 4862/4885PAOX 4327/4885TDP1 19/4885 |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | CHRM2 4845/4885PAOX 2756/4885TDP1 911/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | CHRM2 4547/4885PAOX 460/4885TDP1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.